Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.

[1]  R. Alfonso-Cristancho,et al.  Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan. , 2022, Pulmonary pharmacology & therapeutics.

[2]  M. Humbert,et al.  Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients , 2022, European Respiratory Journal.

[3]  C. Galeone,et al.  Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life , 2022, Journal of asthma and allergy.

[4]  L. Cohn.  Can asthma biologics change the course of disease and induce drug-free remission? , 2022, Journal of Allergy and Clinical Immunology.

[5]  K. Kuwano,et al.  Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study , 2022, Journal of asthma and allergy.

[6]  A. Menzies-Gow,et al.  Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab , 2022, Advances in Therapy.

[7]  K. Betts,et al.  Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study. , 2022, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  G. Canonica,et al.  ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study , 2022, Respiratory Research.

[9]  G. Roberts,et al.  Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis , 2022, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  C. Porsbjerg,et al.  Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study , 2022, Journal of asthma and allergy.

[11]  A. Humbles,et al.  Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity , 2021, European Respiratory Journal.

[12]  H. Nagase,et al.  [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES]. , 2022, Arerugi = [Allergy].

[13]  P. Howarth,et al.  Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.

[14]  M. J. Rodríguez-Nieto,et al.  Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study) , 2021, BMC Pulmonary Medicine.

[15]  Juan Wu,et al.  Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. , 2021, Clinical therapeutics.

[16]  T. Hirano,et al.  Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach , 2021, Journal of asthma and allergy.

[17]  G. E. Carpagnano,et al.  Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy , 2021, Biomedicines.

[18]  H. Matsui,et al.  Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use , 2021, The World Allergy Organization journal.

[19]  K. Shinbori,et al.  Effect of Dupilumab on Depression in Asthma with Eosinophilic Chronic Rhinosinusitis in the Japanese Population , 2021, International Archives of Allergy and Immunology.

[20]  R. Alfonso-Cristancho,et al.  Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data , 2021, Clinical and translational allergy.

[21]  S. Quirce,et al.  REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study , 2021, Drugs.

[22]  I. Pavord,et al.  Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. , 2021, The Lancet. Respiratory medicine.

[23]  N. Lombardo,et al.  Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis , 2021, Journal of asthma and allergy.

[24]  S. Korn,et al.  Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to Five Years. , 2021, The journal of allergy and clinical immunology. In practice.

[25]  M. D’Amato,et al.  Benralizumab effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicentre Study. , 2021, The journal of allergy and clinical immunology. In practice.

[26]  Hirofumi Watanabe,et al.  Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.

[27]  W. Busse,et al.  Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma , 2021, European Respiratory Journal.

[28]  J. Upham,et al.  Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.

[29]  K. Fukunaga,et al.  Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma , 2021, Asia Pacific allergy.

[30]  M. Gröger,et al.  Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP , 2021, Clinical and translational allergy.

[31]  T. Welte,et al.  Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months , 2021, Journal of asthma and allergy.

[32]  N. Kobayashi,et al.  High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.

[33]  M. Idzko,et al.  Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes , 2021, Journal of asthma and allergy.

[34]  I. Pavord,et al.  Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: a meta-analysis. , 2021, The journal of allergy and clinical immunology. In practice.

[35]  K. Kuwano,et al.  Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study , 2021, Journal of asthma and allergy.

[36]  T. Casale,et al.  Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[37]  F. Albers,et al.  Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics , 2021, Respiratory Research.

[38]  B. Beghé,et al.  Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program , 2021, Journal of asthma and allergy.

[39]  K. Samitas,et al.  Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study. , 2021, Allergy and Asthma Proceedings.

[40]  P. Howarth,et al.  Real‐world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[41]  H. Iwamoto,et al.  Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study. , 2021, Respiratory investigation.

[42]  Y. Morishima,et al.  Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma , 2021, PloS one.

[43]  O. Resta,et al.  Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma , 2021, Scientific Reports.

[44]  Jonathan W. Inselman,et al.  Asthma Patients Who Stop Asthma Biologics Have a Similar Risk Of Asthma Exacerbations as Those Who Continue Asthma Biologics. , 2021, The journal of allergy and clinical immunology. In practice.

[45]  W. Busse,et al.  Benralizumab for Adolescent Patients with Severe, Eosinophilic Asthma: Safety and Efficacy after Three Years of Treatment. , 2021, The Journal of allergy and clinical immunology.

[46]  C. Jenkins,et al.  Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. , 2021, The journal of allergy and clinical immunology. In practice.

[47]  F. Albers,et al.  Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials , 2021, Respiratory Research.

[48]  M. D’Amato,et al.  Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression , 2021, Journal of asthma and allergy.

[49]  A. Nanzer,et al.  The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. , 2021, The journal of allergy and clinical immunology. In practice.

[50]  J. Bousquet,et al.  Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. , 2021, The journal of allergy and clinical immunology. In practice.

[51]  G. Canonica,et al.  Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. , 2020, The Lancet. Respiratory medicine.

[52]  A. Nanzer,et al.  Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma , 2020, Allergy.

[53]  A. Poznańska,et al.  Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation , 2020, Journal of asthma and allergy.

[54]  A. Moreira,et al.  Real‐life study in non‐atopic severe asthma patients achieving disease control by omalizumab treatment , 2020, Allergy.

[55]  K. Bergmann,et al.  Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma , 2020, Journal of asthma and allergy.

[56]  E. Bel,et al.  Long-term therapy response to anti-interleukin-5 biologics in severe asthma - a real-life evaluation. , 2020, Journal of Allergy and Clinical Immunology: In Practice.

[57]  A. Yokoyama,et al.  Japanese guidelines for adult asthma 2020. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[58]  H. Ortega,et al.  Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base. , 2020, Allergy and asthma proceedings.

[59]  A. Douiri,et al.  Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[60]  P. Howarth,et al.  Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis , 2020, European Respiratory Journal.

[61]  M. Muratani,et al.  Identification of whole blood gene expressions correlated with responsiveness to benralizumab. , 2020, The Journal of allergy and clinical immunology.

[62]  J. Virchow,et al.  Benralizumab strongly reduces blood basophils in severe eosinophilic asthma , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[63]  Yumei He,et al.  Role of myeloid cells in the regulation of group 2 innate lymphoid cell‐mediated allergic inflammation , 2020, Immunology.

[64]  C. Olveira,et al.  Real-life experience with benralizumab during 6 months , 2020, BMC Pulmonary Medicine.

[65]  A. Didier,et al.  Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[66]  K. Okubo,et al.  Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. , 2020, The journal of allergy and clinical immunology. In practice.

[67]  E. Bel,et al.  Treatment Eligibility of Real-life Mepolizumab-treated Severe Asthma Patients. , 2020, The journal of allergy and clinical immunology. In practice.

[68]  A. Nanzer,et al.  Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[69]  S. Korn,et al.  Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab , 2020, Drug Safety.

[70]  M. Humbert,et al.  Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme , 2020, European Respiratory Journal.

[71]  F. Albers,et al.  Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma , 2020, Allergy.

[72]  S. Fujieda,et al.  The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[73]  S. Fujieda,et al.  Dupilumab: Basic aspects and applications to allergic diseases. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[74]  H. Ortega,et al.  Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs , 2020, Journal of asthma and allergy.

[75]  I. Pavord,et al.  An Expert Consensus Framework for Asthma Remission as a Treatment Goal. , 2019, The Journal of allergy and clinical immunology.

[76]  M. Humbert,et al.  Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma , 2019, Advances in Therapy.

[77]  G. Passalacqua,et al.  Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real‐life observation , 2019, Allergy.

[78]  J. Schreiber,et al.  The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study , 2019, Advances in Therapy.

[79]  P. Campo,et al.  Severe asthma phenotypes in patients controlled with omalizumab: A real-world study. , 2019, Respiratory medicine.

[80]  G. Canonica,et al.  One year of mepolizumab. Efficacy and safety in real-life in Italy. , 2019, Pulmonary pharmacology & therapeutics.

[81]  F. Albers,et al.  Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study. , 2019, Clinical therapeutics.

[82]  Harjinder Singh,et al.  Long-Term Evaluation of Response to Omalizumab Therapy in Real-Life by a Novel Multi-Modular Approach - The REALITY Study. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[83]  F. Albers,et al.  The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma , 2019, Allergy.

[84]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[85]  H. Hammad,et al.  The Cytokines of Asthma. , 2019, Immunity.

[86]  G. Dranoff,et al.  GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. , 2019, Immunity.

[87]  R. Savino,et al.  Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study. , 2019, Pulmonary pharmacology & therapeutics.

[88]  S. Sridhar,et al.  Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases , 2019, Respiratory Research.

[89]  W. Busse,et al.  Anti–IL‐5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison , 2019, The Journal of allergy and clinical immunology.

[90]  W. Busse,et al.  Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. , 2019, The journal of allergy and clinical immunology. In practice.

[91]  M. Adachi,et al.  Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[92]  H. Makita,et al.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. , 2019, The Lancet. Respiratory medicine.

[93]  P. Howarth,et al.  Randomised controlled trials in severe asthma: selection by phenotype or stereotype , 2018, European Respiratory Journal.

[94]  D. Husereau,et al.  Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review , 2018, European Respiratory Journal.

[95]  E. Bleecker,et al.  Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma , 2018, European Respiratory Journal.

[96]  K. Ohta,et al.  Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. , 2018, Respiratory medicine.

[97]  Y. Okamoto,et al.  Amphiregulin‐Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis , 2018, Immunity.

[98]  A. Yorgancioglu,et al.  Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial , 2018, International Archives of Allergy and Immunology.

[99]  B. Chipps,et al.  Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[100]  M. Al-Ahmad,et al.  "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma , 2018, Medical Principles and Practice.

[101]  E. Bleecker,et al.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.

[102]  P. Berger,et al.  Lung function parameters in omalizumab responder patients: An interesting tool? , 2017, Allergy.

[103]  Oliver N Keene,et al.  Biomarkers for severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.

[104]  C. Picado,et al.  Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma , 2017, Thorax.

[105]  I. Abraham,et al.  "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. , 2017, The journal of allergy and clinical immunology. In practice.

[106]  L. Macchia,et al.  Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. , 2017, Respiratory medicine.

[107]  A. Klion.  Recent advances in understanding eosinophil biology , 2017, F1000Research.

[108]  W. Busse,et al.  A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy , 2017, The Journal of allergy and clinical immunology.

[109]  M. Scalese,et al.  Can the response to Omalizumab be influenced by treatment duration? A real-life study. , 2017, Pulmonary pharmacology & therapeutics.

[110]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[111]  T. Hirano,et al.  A trial of oral corticosteroids for persistent systemic and airway inflammation in severe asthma , 2017, Immunity, inflammation and disease.

[112]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[113]  N. Graham,et al.  Commonality of the IL-4/IL-13 pathway in atopic diseases , 2017, Expert review of clinical immunology.

[114]  S. Srivastava,et al.  Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. , 2017, Respiratory medicine.

[115]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[116]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[117]  H. Ortega,et al.  Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. , 2016, Clinical therapeutics.

[118]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[119]  E. Naredo,et al.  Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions , 2016, Annals of the rheumatic diseases.

[120]  I. Abraham,et al.  ‘Real‐life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review , 2016, Allergy.

[121]  H. Kuo,et al.  Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study , 2016, BMC Pulmonary Medicine.

[122]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[123]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[124]  I. Pavord,et al.  Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. , 2014, The Journal of allergy and clinical immunology.

[125]  M. Molimard,et al.  Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. , 2012, Respiratory medicine.

[126]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[127]  G. Braunstahl,et al.  The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. , 2013, Respiratory medicine.

[128]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[129]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[130]  J. Benichou,et al.  Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. , 2013, Chest.

[131]  Y. Minakata,et al.  Predictors for identifying the efficacy of systemic steroids on sustained exhaled nitric oxide elevation in severe asthma. , 2013, Allergology international : official journal of the Japanese Society of Allergology.

[132]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[133]  N. Tzanakis,et al.  Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. , 2012, Pulmonary pharmacology & therapeutics.

[134]  S. Spector,et al.  A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. , 2011, The Journal of allergy and clinical immunology.

[135]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[136]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[137]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[138]  M. Palmqvist,et al.  After 6 years with Xolair; a 3‐year withdrawal follow‐up , 2010, Allergy.

[139]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[140]  K. Takatsu,et al.  Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. , 2009, Human antibodies.

[141]  F. Simons,et al.  American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. , 2007, The Journal of allergy and clinical immunology.

[142]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[143]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[144]  J. Bousquet,et al.  Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[145]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[146]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[147]  E. Chilvers,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma , 2004, Allergy.

[148]  L. Boulet,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR , 2004, Allergy.

[149]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[150]  C. Bizer,et al.  Eosinophils Express Functional IL-13 in Eosinophilic Inflammatory Diseases1 , 2002, The Journal of Immunology.

[151]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[152]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[153]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[154]  C. Davis,et al.  Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. , 1999, The Journal of pharmacology and experimental therapeutics.

[155]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[156]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.